To access this element change to forms mode OFF
Grant Award View - GA70318
Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of...
GA ID:
GA70318
Agency:
Department of Health and Aged Care
Approval Date:
19-Nov-2019
Publish Date:
5-Feb-2020
Category:
Health and Medical Research
Grant Term:
1-Feb-2020 to 31-Jan-2024
Value (AUD):
$1,057,839.75
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF International Clinical Trials_PRC2_funding_commencing_2019
Grant Activity:
Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial (COBRRA)
Purpose:
Blood clots in leg veins and lung arteries decrease quality of life of patients and may cause death. The best way to prevent recurrent clots is with blood thinning medications. A side effect of blood thinning is bleeding. Two new drugs which prevent recurrent clots are accepted as standard of care. However, it is not clear which drug results in fewer bleeding events. We will study patients with blood clots to determine which of these drugs is safer and results in less bleeding events.
GO ID:
GO Title:
Medical Research Future Fund – International Clinical Trial Collaborations Grant Opportunity
Internal Reference ID:
MRF1192408
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Camperdown
Postcode:
2050
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA